Quest Diagnostics (NYS: DGX) is expected to report Q4 earnings on Jan. 23. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Quest Diagnostics's revenues will wither -2.2% and EPS will contract -13.0%.

The average estimate for revenue is $1.83 billion. On the bottom line, the average EPS estimate is $1.07.


Revenue details
Last quarter, Quest Diagnostics chalked up revenue of $1.85 billion. GAAP reported sales were 2.9% lower than the prior-year quarter's $1.91 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $1.18. GAAP EPS of $1.01 for Q3 were 6.5% lower than the prior-year quarter's $1.08 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 42.2%, 10 basis points worse than the prior-year quarter. Operating margin was 19.1%, 80 basis points better than the prior-year quarter. Net margin was 8.8%, 20 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $7.52 billion. The average EPS estimate is $4.47.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 546 members out of 580 rating the stock outperform, and 34 members rating it underperform. Among 189 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 183 give Quest Diagnostics a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Quest Diagnostics is hold, with an average price target of $62.03.

Is Quest Diagnostics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

The article What Does Wall Street See for Quest Diagnostics's Q4? originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends Quest Diagnostics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investing in Emerging Markets

Learn to invest in a globalized world.

View Course »

Investment Strategies

What's your investing game plan?

View Course »

Add a Comment

*0 / 3000 Character Maximum